Evolutionary Genomics (Evolutionary Genomics) Total Assets : $2.35 Mil (As of Dec. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Total Assets?

Evolutionary Genomics's Total Assets for the quarter that ended in Dec. 2022 was $2.35 Mil.

Total Assets is connected with ROA %. Evolutionary Genomics's annualized ROA % for the quarter that ended in Dec. 2022 was -53.01%. Total Assets is also linked to Revenue through Asset Turnover. Evolutionary Genomics's Asset Turnover for the quarter that ended in Dec. 2022 was 0.00.

Evolutionary Genomics Total Assets Historical Data

The historical data trend for Evolutionary Genomics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Total Assets Chart

Evolutionary Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

4.39

4.24

3.99

2.93

2.35

Evolutionary Genomics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Total Assets	Get a 7-Day Free Trial															2.93	3.51	3.09	2.69	2.35

Evolutionary Genomics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Evolutionary Genomics's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-5.592	+	7.946
	=	2.35

Evolutionary Genomics's Total Assets for the quarter that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2022 )	+	Total Liabilities (Q: Dec. 2022 )
	=	-5.592	+	7.946
	=	2.35

Evolutionary Genomics (OTCPK:FNAM) Total Assets Explanation

Total Assets is connected with ROA %.

Evolutionary Genomics's annualized ROA % for the quarter that ended in Dec. 2022 is

ROA %	=	Net Income (Q: Dec. 2022 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Dec. 2022 ))	/ count )
	=	-1.336	/	( (2.687	+	2.354)	/ 2 )
	=	-1.336	/	2.5205
	=	-53.01 %

Note: The Net Income data used here is four times the quarterly (Dec. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Evolutionary Genomics's Asset Turnover for the quarter that ended in Dec. 2022 is

	Asset Turnover
=	Revenue (Q: Dec. 2022 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Dec. 2022 ))	/ count )
=	0	/	( (2.687	+	2.354)	/ 2 )
=	0	/	2.5205
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Evolutionary Genomics Total Assets Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolutionary Genomics (Evolutionary Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website

https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

Executives

Steve B Warnecke	director, 10 percent owner, officer: Chairman, CEO	C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff	director	4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier	officer: Secretary / Treasurer	1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess	director	7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz	director, 10 percent owner	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess	director, 10 percent owner, officer: President/CEO	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita	director, officer: Secretary/Treasurer/CFO	5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines